# Successful Management of Eagle Syndrome in a Patient With Repeated Office-Based, Ultrasound-Guided Nerve Blocks: A Case Report

**Authors:** Abdullah Nisar, Ali Sarfraz Siddiqui

PMC · DOI: 10.7759/cureus.102616 · Cureus · 2026-01-30

## TL;DR

A 65-year-old woman with Eagle syndrome found long-term pain relief through repeated ultrasound-guided nerve blocks.

## Contribution

Demonstrates successful non-surgical management of Eagle syndrome using office-based ultrasound-guided nerve blocks.

## Key findings

- The patient experienced significant pain relief after repeated ultrasound-guided glossopharyngeal nerve blocks.
- Symptoms were managed for approximately three months following the procedure.
- Medications provided only temporary and partial relief prior to the nerve blocks.

## Abstract

Eagle syndrome is a form of glossopharyngeal neuralgia, usually seen in older adults and characterized by pain in the throat, side of the face, and neck due to an elongated styloid process or calcified stylohyoid ligament. This condition can be managed with multimodal analgesia by multidisciplinary teams and may require surgical intervention for definitive relief. A 65-year-old female presented to the pain management clinic with chronic recurrent left-sided submandibular and neck pain. The pain was moderate in intensity (numeric rating scale (NRS) 5/10), episodic, sharp, burning, and electric shock-like in nature, and was associated with coughing and swallowing. She obtained only temporary and partial relief from medications. Her symptoms were successfully managed with repeated office-based ultrasound-guided glossopharyngeal nerve blocks using 3 ml of 0.25% ropivacaine and 4 mg dexamethasone. Significant improvement was maintained for approximately three months after the procedure.

## Linked entities

- **Chemicals:** ropivacaine (PubChem CID 71273), dexamethasone (PubChem CID 5743)
- **Diseases:** Eagle syndrome (MONDO:0023035), glossopharyngeal neuralgia (MONDO:0016372)

## Full-text entities

- **Diseases:** infection (MESH:D007239), endocrine disorders (MESH:D004700), end-stage renal disease (MESH:D007676), ossification (MESH:C562735), trigeminal nerve block (MESH:D020433), cough (MESH:D003371), headaches (MESH:D006261), inflammatory (MESH:D007249), trauma (MESH:D014947), dysphagia (MESH:D003680), syncope (MESH:D013575), Pain (MESH:D010146), Glossopharyngeal neuralgia (MESH:D020435), seizures (MESH:D012640), orofacial pain syndromes (MESH:D005157), submandibular and neck pain (MESH:D019547), bradycardia (MESH:D001919), Eagle Syndrome (MESH:C538010), trigeminal neuralgia (MESH:D014277), chronic pain (MESH:D059350), hoarseness (MESH:D006685)
- **Chemicals:** ropivacaine (MESH:D000077212), dexamethasone (MESH:D003907), duloxetine (MESH:D000068736), pregabalin (MESH:D000069583), gabapentin (MESH:D000077206), tramadol (MESH:D014147), methylprednisolone (MESH:D008775), Carbamazepine (MESH:D002220), oxcarbazepine (MESH:D000078330)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12949947/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12949947/full.md

---
Source: https://tomesphere.com/paper/PMC12949947